Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation
AUTOR(ES)
Portal, Vera Lúcia, Moriguchi, Emílio H., Vieira, José Luiz da Costa, Schio, Sadi, Mastalir, Eduardo T., Buffé, Fabiana, Bortolini, Eleni Borges, Brüch, Ricardo Santalucia, Rodrigues, Rubem
FONTE
Arquivos Brasileiros de Cardiologia
DATA DE PUBLICAÇÃO
2003-02
RESUMO
OBJECTIVE: To study the differences between fluvastatin and pravastatin regarding LDL susceptibility to oxidation, plasma levels of total cholesterol (TC), HDL-C, LDL-C and triglycerides (TG) in hypercholesterolemic patients with established coronary heart disease (CHD). METHODS: A double-blind randomized parallel study was conducted that included 41 hypercholesterolemic outpatients with CHD treated at the Instituto de Cardiologia do Rio Grande do Sul. The inclusion criteria were LDL-C above 100 mg/dL and triglycerides below 400 mg/dL based on 2 measures. After 4 weeks on a low cholesterol diet, those patients that fullfilled the inclusion criteria were randomized into 2 groups: the fluvastatin group (fluvastatin 40 mg/day) and the pravastatin group (pravastatin 20 mg/day), for 24 weeks of treatment. LDL susceptibility to oxidation was analyzed with copper-induced production of conjugated dienes (Cu2+) and water-soluble free radical initiator azo-bis (2'-2'amidinopropanil) HCl (AAPH). Spectroscopy nuclear magnetic resonance was used for determination of lipids. RESULTS: After 24 weeks of drug therapy, fluvastatin and pravastatin significantly reduced LDL susceptibility to oxidation as demonstrated by the reduced rate of oxidation (azo and Cu) and by prolonged azo-induced lag time (azo lag). The TC, LDL-C, and TG reduced significantly and HDL-C increased significantly. No differences between the drugs were observed. CONCLUSION: In hypercholesterolemic patients with CHD, both fluvastatin and pravastatin reduced LDL susceptibility to oxidation.
Documentos Relacionados
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
- Effect of Insulin on Sterol and Fatty Acid Synthesis and Hydroxymethylglutaryl CoA Reductase Activity in Mammalian Cells Grown in Culture
- Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo
- HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway